Toujeo
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot. This results in a flatter, more prolonged pharmacokinetic and pharmacodynamic profile. Insulin release is therefore slower, allowing for less frequent or reduced-dose administration. The key improvement in Toujeo’s clinical profile compared to the original formulation is reduced nocturnal hypoglycemia.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Toujeo : Diabetes type 2
12 Toujeo : Diabetes type 1
LIST OF FIGURES
9 Figure 1: Toujeo for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Toujeo
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Toujeo
15 Figure 4: Toujeo for type 1 diabetes – SWOT analysis
16 Figure 5: Datamonitor Healthcare’s drug assessment of Toujeo in type 1 diabetes
17 Figure 6: Datamonitor Healthcare’s drug assessment of Toujeo in type 1 diabetes
LIST OF TABLES
4 Table 1: Toujeo drug profile
6 Table 2: Outline of Phase III trials investigating Toujeo in the treatment of type 2 diabetes
8 Table 3: Comparison of hypoglycemia rates between Lantus and Toujeo
13 Table 4: Toujeo drug profile
14 Table 5: Toujeo pivotal trial data in type 1 diabetes
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Suglat 
Sign up to the